Drugs / H077
last change Aug 2025 re-read 2 minutes ago

H077

Developed for
benign prostatic hyperplasia
Investigated by
Shanghai Huilun Pharmaceutical Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT07146386 Aug 2025 → Jan 2027 expected benign prostatic hyperplasia Shanghai Huilun Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as H077 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07146386
Route Oral orally once daily” NCT07146386